Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T CORE2401 first-line mFOLFOX6 plus cetuximab versus mFOLFOX6 plus bevacizumab in RAS/BRAF wild-type metastatic right-sided colon cancer
jRCT1021240067Phase 2Suspended
- Sponsor
- Tohoku Clinical Oncology Research and Educational Society
- Start
- Jan 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab, bevacizumab, fluorouracil, folinic acid and oxaliplatin in colorectal cancer (CRC) and colon cancer (2 arms), sponsored by Tohoku Clinical Oncology Research and Educational Society. Primary endpoint: Response rate. Started Jan 2026; status: suspended.
02
Drugs
cetuximabbevacizumabfluorouracilfolinic acidoxaliplatin
03
Conditions
colorectal cancer (CRC)colon cancer
Beyond the preview
Go deeper on jRCT1021240067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1021240067.